Addex Therapeutics Gross Margin 2021-2025 | ADXN
Current and historical gross margin for Addex Therapeutics (ADXN) over the last 10 years. The current gross profit margin for Addex Therapeutics as of March 31, 2025 is %.
| Addex Therapeutics Gross Margin Historical Data |
| Date |
TTM Revenue |
TTM Gross Profit |
Gross Margin |
| 2024-12-31 |
$0.00B |
0 |
0.00% |
| 2024-09-30 |
$0.00B |
0 |
0.00% |
| 2024-06-30 |
$0.00B |
0 |
0.00% |
| 2024-03-31 |
$0.00B |
$0.00B |
100.00% |
| 2023-12-31 |
$0.00B |
$0.00B |
100.00% |
| 2023-09-30 |
$0.00B |
$0.00B |
100.00% |
| 2023-06-30 |
$0.00B |
$0.00B |
100.00% |
| 2023-03-31 |
$0.00B |
$0.00B |
100.00% |
| 2022-12-31 |
$0.00B |
$0.00B |
100.00% |
| 2022-09-30 |
$0.00B |
0 |
0.00% |
| 2022-06-30 |
$0.00B |
$0.00B |
100.00% |
| 2022-03-31 |
$0.00B |
$0.00B |
100.00% |
| 2021-12-31 |
$0.00B |
$0.00B |
100.00% |
| 2021-09-30 |
$0.01B |
$0.01B |
100.00% |
| 2021-06-30 |
$0.00B |
$0.00B |
100.00% |
| 2021-03-31 |
$0.00B |
$0.00B |
100.00% |
| 2020-12-31 |
$0.00B |
$0.00B |
100.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Drug Manufacturing |
$0.008B |
$0.000B |
|
Addex Therapeutics Ltd is a clinical-stage pharmaceutical company. It is focused on the development and commercialization of small molecule drugs for neurological disorders. The company's lead drug candidate includes dipraglurant, ADX71149 which are in clinical stage. Its Preclinical programs include GABAB PAM for CMT1A, mGlu7 NAM for PTSD, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson's disease and mGlu3 PAM for neurodegenerative disorders. GABAB PAM program has been licensed to Indivior PLC for the treatment of addiction. Addex Therapeutics Ltd is based in Geneva, Switzerland.
|
